Combination therapy with two or more csDMARDs may be effective when single-DMARD treatments are unsuccessful or in RA patients presenting with several prognostic factors, such as elevated levels of inflammatory markers (e.g., Erythrocyte Sedimentation Rate [ESR] and C-reactive protein [CRP]), multiple swollen joints, and extra-articular manifestations. Here, CRP is linked to rheumatoid arthritis.